financetom
Business
financetom
/
Business
/
Procter & Gamble misses sales expectations on slowing demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Procter & Gamble misses sales expectations on slowing demand
Jul 30, 2024 4:30 AM

(Reuters) -Procter & Gamble missed Wall Street expectations for fourth-quarter sales on Tuesday, on weak demand for its skincare products in major market China and waning price benefitsin the U.S. and Europe for its home care products.

Shares of the Tide detergent maker fell 2.3% in premarket trading.

P&G has scaled back on further price hikes and instead have been spending heavily to launch newer products like Tide Evo and diaper brand Luvs Platinum Protection that appeal to consumers looking for cheaper daily-use products.

Last week, Nestle and Unilever reported first-half sales growth below expectations, as their attempts to raise prices more slowly have not been enough to win back cost-conscious customers.

Fourth-quarter net sales for P&G slipped to $20.53 billion from $20.55 billion a year ago. Analysts had expected $20.74 billion, according to LSEG data.

On an adjusted basis, it earned $1.40 per share, beating estimates of $1.37. The company said it expects to repurchase $6 to $7 billion of common shares in fiscal 2025.

P&G reported a 1% rise in overall volumes in the fourth quarter, while the average prices across its product categories also rose 1%.

The consumer goods giant expects core earnings to rise between $6.91 and $7.05 in fiscal 2025, compared with analysts' expectations of $6.97 per share.

P&G expects sales growth in the range of 2% to 4% for fiscal 2025, compared with analysts' expectation of a 3.04% rise.

(Reporting by Ananya Mariam Rajesh in Bengaluru; Editing by Arun Koyyur)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved